SciCombinator

Discover the most talked about and latest scientific content & concepts.

Management of clinical Stage I nonseminomatous germ cell tumors

Expert review of anticancer therapy | 17 Jun 2014

S Isharwal and MC Risk
Abstract
Therapeutic options for clinical Stage I nonseminomatous germ cell tumor include active surveillance, adjuvant chemotherapy and retroperitoneal lymph node dissection (RPLND). Lymphovascular invasion (LVI) determines risk of recurrence, as those without LVI have 15% risk of relapse on surveillance while those with LVI have a 50% risk. This stratifies patients into high risk(LVI+) and low risk(LVI-) groups which direct treatment recommendations. Surveillance is preferred for those with low risk disease, and is an option for those with high risk disease, as at least half are over-treated with other options. Adjuvant chemotherapy is an option for all patients as it can eradicate micrometastatic disease and reduce recurrence by at least 90%. RPLND benefits patients with low volume retroperitoneal disease with a cure rate of RPLND alone at approximately 70%. All three treatment modalities have similar survival rates approaching 100% but differing potential morbidities, which, along with patient preferences and compliance, should guide treatment decisions.
Tweets*
0
Facebook likes*
0
Reddit*
0
News coverage*
0
Blogs*
0
SC clicks
1
Concepts
Mediastinal germ cell tumor, Medicine, Cure, Germ cell, Cancer, Oncology, Germ cell tumor
MeSH headings
-
comments powered by Disqus

* Data courtesy of Altmetric.com